Yahoo · Oct 28, 2026
Sellas’ GPS Trial Records 80th Event — Retail Says ‘Completely Irrational Sell Off’ As SLS Stock Tanks 18%
Sellas said that its Phase 3 Regal trial of GPS recorded its 80th event, triggering the final analysis.
SL
NASDAQ · SLS
SELLAS Life Sciences Group, Inc.
Healthcare · Biotechnology
$10.16
Down-$0.48 (-4.68%)
Updated Oct 31, 2026, 1:52 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 211.34M
- P/E ratio
- -7.53
- Dividend yield
- 0.00%
- 52-week range
- $1.39 – $15.88
- Volume
- 8.35M
- Avg. volume
- 4.07M
Price performance · SLS
SLS price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
SLS closed at $10.16 after 20 trading sessions, down 13.50% for the selected period.
- Last close
- $10.16
- Period change
- -13.50%
- Period low
- $9.98
- Period high
- $12.41
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $10.42 | $11.0949 | $9.85 | $10.155 | 8.35M |
| Oct 28, 2026 | $12.20 | $12.44 | $9.705 | $10.38 | 23.77M |
| Oct 27, 2026 | $11.33 | $12.29 | $11.25 | $12.17 | 6.22M |
| Oct 26, 2026 | $11.535 | $11.70 | $11.18 | $11.34 | 3.21M |
| Oct 23, 2026 | $11.29 | $11.59 | $11.08 | $11.54 | 3.28M |
| Oct 22, 2026 | $11.91 | $12.37 | $11.12 | $11.35 | 6.51M |
| Oct 21, 2026 | $12.07 | $12.335 | $11.81 | $12.14 | 5.66M |
| Oct 20, 2026 | $10.045 | $12.01 | $9.95 | $11.98 | 10.26M |
| Oct 19, 2026 | $10.10 | $10.85 | $10.04 | $10.49 | 5.61M |
| Oct 16, 2026 | $11.20 | $11.24 | $9.7501 | $9.98 | 15.82M |
| Oct 15, 2026 | $11.50 | $11.92 | $11.15 | $11.34 | 4.66M |
| Oct 14, 2026 | $12.205 | $12.4399 | $11.71 | $11.88 | 4.74M |
| Oct 13, 2026 | $11.74 | $12.7031 | $11.69 | $12.41 | 6.4M |
| Oct 12, 2026 | $11.58 | $12.14 | $11.4751 | $11.93 | 4.04M |
| Oct 9, 2026 | $11.38 | $11.805 | $11.26 | $11.65 | 4.18M |
| Oct 8, 2026 | $11.17 | $11.34 | $10.71 | $11.26 | 4.21M |
| Oct 7, 2026 | $11.28 | $11.54 | $11.1451 | $11.31 | 3.14M |
| Oct 6, 2026 | $11.63 | $11.6712 | $11.111 | $11.34 | 3.98M |
| Oct 5, 2026 | $11.77 | $11.77 | $11.35 | $11.63 | 4.51M |
| Oct 2, 2026 | $11.50 | $12.00 | $11.38 | $11.74 | 3.85M |
Latest SLS news
The latest Smart Investors Daily articles mentioning SLS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SLS research
Overview
Company profile and research snapshot.
Company profile
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 16, 2025 | Maxim Group | Buy | — |
| Nov 22, 2023 | Cantor Fitzgerald | Overweight | — |
| Sep 7, 2023 | Cantor Fitzgerald | Overweight | — |
| Nov 15, 2022 | Alliance Global Partners | Buy | — |
| Jun 28, 2022 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Sellas Sinks 18% as Phase 3 Leukemia Trial Reaches “Critical Milestone” Ahead of Final Data
Key TakeawaysSellas shares fell 18% today after the company said its Phase 3 REGAL trial in acute myeloid leukemia reached the 80th death, which triggers the trial’s final analysis. The drop looks like investors selling the news after a 223% run this year, because the overall-survival result is still to come.
Yahoo · Oct 28, 2026
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
- Reaching the Pre-Specified 80th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial - - Company to Report Topline Primary Endpoint Results this Quarter - NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the pivotal Phase 3 REGAL trial evaluating galinpepimut-
Benzinga · Oct 28, 2026
SELLAS Life Sciences Stock Stumbles: What's Going On?
SELLAS Life Sciences Group shares are falling Wednesday as the company's Phase 3 leukemia study moves toward its final analysis.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
